本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Nuvectis Pharma, Inc.

6.56
+0.03000.46%
盘后6.560.00000.00%16:10 EDT
成交量:3.59万
成交额:23.61万
市值:1.67亿
市盈率:-5.67
高:6.75
开:6.54
低:6.43
收:6.53
52周最高:11.80
52周最低:4.44
股本:2,545.68万
流通股本:1,453.66万
量比:0.72
换手率:0.25%
股息:- -
股息率:- -
每股收益(TTM):-1.1568
每股收益(LYR):-1.1103
净资产收益率:-150.12%
总资产收益率:-63.38%
市净率:9.90
市盈率(LYR):-5.91

数据加载中...

2023/03/27

[修订]年度报告

10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/08

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2023/03/07

重要事件披露

8-K - Current report
2023/02/13

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/02/13

超过5%披露

SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/01/09

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/11/08

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/11/08

重要事件披露

8-K - Current report
2022/08/23

SEC问询函

CORRESP [Cover] - Correspondence
2022/08/15

招股说明书

S-1 - General form for registration of securities under the Securities Act of 1933
2022/08/10

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/08/05

重要事件披露

8-K - Current report
2022/07/29

重要事件披露

8-K - Current report
2022/05/12

季度报告

10-Q - Quarterly report [Sections 13 or 15(d)]
2022/05/11

重要事件披露

8-K - Current report
2022/03/29

超过5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/03/28

超过5%披露

SC 13D - General statement of acquisition of beneficial ownership
2022/03/24

员工持股计划

S-8 - Securities to be offered to employees in employee benefit plans
2022/03/23

年度报告

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2022/03/22

重要事件披露

8-K - Current report